Skip to main content
Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California
Published Web Location
http://europepmc.org/articles/PMC3997554?pdf=renderNo data is associated with this publication.
Abstract
Background: Pyrazinamide (PZA) is a first line agent for the treatment of active tuberculosis. PZA is also considered a potent companion drug for newer regimens under development. There are limited data on the demographic, clinical, and pathogen characteri
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.